Scale-up of antiretroviral therapy (ART) and the growing number of long-term treated patients may favor multi-HIV drug resistance (HIVDR) in resource-limited settings. Understanding the burden of HIVDR with ART-exposure may provide new insights for an effective long-term management of infected patients.
Nanfack, A.j., Takou, D., Fokam, J., Salpini, R., Santoro, M., Cappelli, G., et al. (2016). HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. CURRENT HIV RESEARCH, 15(1), 66-73 [10.2174/1570162X14666161230105417].
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design
NANFACK, AUBIN JOSEPH;SALPINI, ROMINA;SANTORO, MARIA;CECCHERINI SILBERSTEIN, FRANCESCA;COLIZZI, VITTORIO;PERNO, CARLO FEDERICO;
2016-12-29
Abstract
Scale-up of antiretroviral therapy (ART) and the growing number of long-term treated patients may favor multi-HIV drug resistance (HIVDR) in resource-limited settings. Understanding the burden of HIVDR with ART-exposure may provide new insights for an effective long-term management of infected patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
2017_HIV-1 Drug Susceptibility_Curr HIV Res_Nanfack.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
286.41 kB
Formato
Adobe PDF
|
286.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
